SOPHiA GENETICS Expands Global Adoption of Liquid Biopsy Testing

SOPHiA GENETICS has announced a significant milestone in the adoption of its cancer testing applications, MSK-ACCESS® and MSK-IMPACT®, powered by SOPHiA DDM™. In a press release, the company revealed that 37 prominent healthcare institutions worldwide have adopted these applications, which include both Liquid Biopsy and Solid Tumor testing.

The MSK-ACCESS® application, launched just ten months ago, has been adopted by 34 institutions, enabling them to conduct Liquid Biopsy testing within their own facilities. This decentralized approach offers a less-invasive option for genomic testing, potentially reducing costs and turnaround times while allowing institutions to maintain control over patient data.

Among the institutions adopting these technologies are Heidelberg University Hospital in Germany, Hospital del Mar in Spain, and Jewish General Hospital in Canada. The complementary MSK-IMPACT® application has also garnered interest from leading organizations globally, including the Jiménez Díaz Foundation University Hospital in Spain and Sofiva Genomics in Taiwan.

SOPHiA GENETICS, in partnership with Memorial Sloan Kettering Cancer Center, aims to leverage its SOPHiA DDM™ Platform to enhance precision medicine worldwide, providing healthcare providers with access to cutting-edge cancer testing capabilities.